Experts at HLTH Europe discussed how to ensure patients have trust in the EHDS to ensure a successful roll-out.

egnite has launched the CardioCare Research Suite, an advanced component of its flagship platform, aimed at enhancing patient identification processes for cardiovascular clinical trials. This tool is ...

Pfizer's recent trial termination makes it yet another company facing challenges with CD47 studies in oncology.

Javara has formed a collaboration with Cape Fear Valley Health to enhance clinical trial access for patients in Fayetteville, North Carolina.

FELIQS has concluded a $9m Series A funding round, a significant step towards advancing the FLQ-101 clinical programme for ROP.

OpRegen is a suspension of embryonic stem cell-derived RPE cells restoring visual function in degenerative retinal pathologies.

Assembly Biosciences has dosed the first subject in the Phase Ia/b study’s Phase Ib portion, evaluating ABI-1179.

The companies are also running an open-label study to evaluate the long-term efficacy and safety of the psychedelic in ...

INmune Bio said that a subset of Alzheimer's disease patients in the study showed clinical benefit from the therapy.

Amgen and Zai Lab have reported that the Phase III FORTITUDE-101 trial, assessing bemarituzumab with chemotherapy, achieved ...

Biogen has commenced dosing in the Phase III PROMINENT trial, assessing the efficacy and safety of the felzartamab drug.

The endometriosis market is expected to grow from $938.0m in 2024 to $2.5 billion in 2034, at a compound annual growth rate ...